42-44-Maps India-Ocimum Biosolutions-Max Neeman International
15 June 2010 | News
42
Maps India
Maps India, a producer and exporter of industrial enzymes, has reported a total revenue of Rs 45 crore in the financial year 2009-2010. With over 150 employees, sophisticated production plant and a dedicated R&D center, it has become a key player in enzymes and microorganisms. A team of 30 scientists is involved in R&D activities at Maps India. It produces a broad range of enzymes and microorganisms at its full-scale production plant spread across 57000 Sq. mt. Maps’ enzymes include amylases, proteases, cellulases, xylanase, glucoamylase, pectinase, catalase and phytase, which are used in versatile industries like textile, leather, baking, alcohol, brewing, detergent, starch and animal feed. Its microorganisms products are used in various applications for effluent treatments, cleaning and odor control, waste degradation, bioaugmentation and bioremediation, and aquaculture.
The company has been investing about Rs 10 crore in Gujarat for expanding its operations. In this regard it has signed a Memorandum of Understanding with the state government.
43
Ocimum Biosolutions
Ocimum Biosolutions has reported sales revenue of Rs 41.47 in the current fiscal year as compared to Rs 47.57 crore in the previous fiscal. The company has invested over Rs 2 crore R&D and so far has filed 65 international patents with seven granted. Ocimum currently has a manpower of 155 people. Ocimum Biosolutions provides comprehensive (research level and GLP-compliant) genomic services, reference databases, and LIMS solutions. Ocimum’s distinct platform “Research as a Service” (RaaS) allows complete outsourcing of genomics – from storing biological samples and performing on demand DNA and RNA based services to validating biomarkers using its proprietary databases and providing data and bioinformatic analysis. The company has been chosen as a global preferred outsourcing provider for more than 75 percent of top 25 pharmaceutical and biotechnology companies and leading research institutes. With its global infrastructures, standardized procedures, capacity, and highly skilled staff, the company is capable of supporting drug development programs from pre-clinical target development and toxicogenomic assessment to clinical biomarker identification and patient stratification.
44
Max Neeman International
Max Neeman International, subsidiary of the Max India Group provides full range of clinical research services with focus on phase I, II, III and IV trials for drugs, devices, nutraceuticals and cosmetics in compliance with ICH GCP standards. The company has accumulated Rs 40 crore as revenue in last financila year.
Max Neeman is based out of six regional offices and has 175 active sites in 22 cities with access to over 900 GCP trained investigators. 90 percent of the total employees are physicians (MDs) and ICH GCP trained. Max Neeman is a 9001:2008 certified organization for site management, monitoring and data management and ISO 27001 certified for Information Security Management System.
The company has evolved into a full service CRO over the past nine years and has followed a process of continuous development. It has successfully completed four US FDA audits for highest enrollment globally and has been successfully audited around 40 times by the sponsor companies.
Maps India
| MD | Piyush Palkhiwala |
 |
| Business | Producer and exporter of industrial enzymes |
|
| Start-up Year | 1975 | |
| Biotech Revenue | Rs 45 crore | |
| Address | 302, Shapath-3, Near GNFC Info Tower,
Sarkhej-Gandhinagar Highway, Ahmedabad - 380054 |
|
| Tel | +91-79-26859971-74 | |
| Fax | +91-79-26859975 |
|
| Website | www.mapsenzymes.com |
Maps India, a producer and exporter of industrial enzymes, has reported a total revenue of Rs 45 crore in the financial year 2009-2010. With over 150 employees, sophisticated production plant and a dedicated R&D center, it has become a key player in enzymes and microorganisms. A team of 30 scientists is involved in R&D activities at Maps India. It produces a broad range of enzymes and microorganisms at its full-scale production plant spread across 57000 Sq. mt. Maps’ enzymes include amylases, proteases, cellulases, xylanase, glucoamylase, pectinase, catalase and phytase, which are used in versatile industries like textile, leather, baking, alcohol, brewing, detergent, starch and animal feed. Its microorganisms products are used in various applications for effluent treatments, cleaning and odor control, waste degradation, bioaugmentation and bioremediation, and aquaculture.
The company has been investing about Rs 10 crore in Gujarat for expanding its operations. In this regard it has signed a Memorandum of Understanding with the state government.
43
Ocimum Biosolutions
| CEO | Anuradha Acharya |
 |
| Business | Bioinformatics tools and services |
|
| Start-up Year | 2000 | |
| Biotech Revenue | Rs 41.47 crore |
|
| Address | 6th Floor, Reliance Classic, Road No 1, Banjara Hills,
Hyderabad - 500 034 |
|
| Tel | +91-40-5562 7200 | |
| Fax | +91-40-5562 7205 | |
| Website | www.ocimumbio.com |
Ocimum Biosolutions has reported sales revenue of Rs 41.47 in the current fiscal year as compared to Rs 47.57 crore in the previous fiscal. The company has invested over Rs 2 crore R&D and so far has filed 65 international patents with seven granted. Ocimum currently has a manpower of 155 people. Ocimum Biosolutions provides comprehensive (research level and GLP-compliant) genomic services, reference databases, and LIMS solutions. Ocimum’s distinct platform “Research as a Service” (RaaS) allows complete outsourcing of genomics – from storing biological samples and performing on demand DNA and RNA based services to validating biomarkers using its proprietary databases and providing data and bioinformatic analysis. The company has been chosen as a global preferred outsourcing provider for more than 75 percent of top 25 pharmaceutical and biotechnology companies and leading research institutes. With its global infrastructures, standardized procedures, capacity, and highly skilled staff, the company is capable of supporting drug development programs from pre-clinical target development and toxicogenomic assessment to clinical biomarker identification and patient stratification.
44
Max Neeman International
| CEO | Dr Ajoy Kumar |  |
| Business | Clinical research services |
|
| Start-up Year | 2001 | |
| Biotech Revenue | Rs 40 crore |
|
| Address | Max House, 1 Dr Jha Marg, Okhla III, New Delhi-110020 |
|
| Tel | +91-11-40772100 | |
| Fax | +91-11-26322846 | |
| Website | www.neeman-medical.com |
Max Neeman International, subsidiary of the Max India Group provides full range of clinical research services with focus on phase I, II, III and IV trials for drugs, devices, nutraceuticals and cosmetics in compliance with ICH GCP standards. The company has accumulated Rs 40 crore as revenue in last financila year.
Max Neeman is based out of six regional offices and has 175 active sites in 22 cities with access to over 900 GCP trained investigators. 90 percent of the total employees are physicians (MDs) and ICH GCP trained. Max Neeman is a 9001:2008 certified organization for site management, monitoring and data management and ISO 27001 certified for Information Security Management System.
The company has evolved into a full service CRO over the past nine years and has followed a process of continuous development. It has successfully completed four US FDA audits for highest enrollment globally and has been successfully audited around 40 times by the sponsor companies.
